Discover What’s Streaming On: Pluribus Episode 5 ended on a cliffhanger so intense that even Carol (Rhea Seehorn) couldn’t help but gasp. Pluribus Episode 5 spoilers ahead. Last week, Vince Gilligan’s ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

If you thought there was no possible way out for Claire Danes’ Aggie in the “The Beast in Me” finale episode, that was by design. Showrunner Howard Gordon — with whom Danes worked on “Homeland” — ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

“The Woman in Cabin 10” is now streaming on Netflix and, like many movie adaptations of books, it makes some key changes — particularly when it comes to the twist of the story. This perhaps goes ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Forbes contributors publish independent expert analyses and insights. Monica is an entertainment reporter covering TV, film, and music. Season 2 of Beauty in Black kicks off with Kimmie as the new ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...